Cell biology and genetics in liver cancer;Biología celular y genética en el cáncer de hígado

Gastroenterologia y Hepatologia

Volumn 30, Issue 6, 2007, Pages 360-369

  Tovar, Victoria ^a   Villanueva, Augusto ^b   Llovet, Josep M ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P13K; TELOMERASE; UNCLASSIFIED DRUG; WNT1 PROTEIN;

CANCER CELL CULTURE; CANCER GENETICS; CANCER STEM CELL; CYTOLOGY; DNA MICROARRAY; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENE MUTATION; GENOME ANALYSIS; HUMAN; HYPOTHESIS; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CIRRHOSIS; METASTASIS; MOLECULAR BIOLOGY; PHENOTYPE; REVIEW; SCINTISCANNING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL;

EID: 34548593568     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13107573     Document Type: Article

References (52)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.
2. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215-9.
4. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339-46.
5. Wong QW, Wong N, Lai PB, To KF, Wong N. Clonal relationship of tumor nodules in hepatocellular carcinoma: a hierarchical clustering analysis of comparative genomic hybridization data. Hum Pathol. 2005;36:893-8.
6. Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis. 2005;26:2050-7.
7. Katoh H, Shibata T, Kokubu A, et al. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol. 2005;43:863-74.
8. Midorikawa Y, Yamamoto S, Ishikawa S, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene. 2006;25:5581-90.
9. Raidl M, Pirker C, Schulte-Hermann R, et al. Multiple chromosomal abnormalities in human liver (pre)neoplasia. J Hepatol. 2004;40:660-8.
10. Haber D, Harlow E. Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet. 1997;16:320-2.
11. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820-3
12. Koo SH, Ihm CH, Kwon KC, Lee JS, Park JW, Kim JW. Microsatellite alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2003;146:139-44.
13. Buetow KH, Sheffield VC, Zhu M, et al. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci USA. 1992;89:9622-6.
14. Tanaka S, Toh Y, Adachi E, Matsumata T, Mori R, Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res. 1993;53:2884-7.
15. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991;51:5520-5.
16. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res. 2006;66:4766-73.
17. Lemmer E, Friedman SL, Llovet JM. Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin Liver Dis. 2006;26:373-84.
18. Xu XR, Huang J, Xu ZG, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA. 2001;98:15089-94.
19. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667-76.
20. Thorgeirsson SS, Lee JS, Grisham JW. Molecular prognostication of liver cancer: end of the beginning. J Hepatol. 2006;44:798-805.
21. Iizuka N, Oka M, Yamada-Okabe H, et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 2003;361:923-9.
22. Paradis V, Bieche I, Dargere D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol. 2003;163:733-41.
23. Llovet J, Chen Y, Wurmbach E, Roayaie S. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV-cirrhosis. Gastroenterology. 2006;131:1758-67.
24. Farazi P, DePinho R. Hepatocellular carcinoma pathogenesis: from genes to environment. Nature reviews. 2006;6:674-87.
25. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005;25:212-25.
26. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-50.
27. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell. 2001;105:391-402.
28. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130-4.
29. Ishizaki Y, Ikeda S, Fujimori M, et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol. 2004;24:1077-83
30. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;155:703-10.
31. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001;411:349-54.
32. Huang S, He J, Zhang X, et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis. 2006;27:1334-40.
33. Osipo C, Miele L. Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC. Cancer Biol Ther. 2006;5:238-9.
34. Pollak MN, Schernhammer ES, Hankinson S. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-18.
35. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene. 2006;25:3787-800.
36. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 2005;205:145-53.
37. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005;43:661-9.
38. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005;41:307-14.
39. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523-30.
40. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology. 1997;25:619-23.
41. Takami T, Uchida U, Kaposi-Novak P, et al. Loss of HGF/CMET signaling pathway accelerates early stages of DEN-induced hepatocarcinogenesis. Hepatology. 2006;44:205A.
42. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
43. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929-40.
44. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;10:8421-5.
45. Jordan C, Guzman M, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-61.
46. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006;441:1068-74.
47. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells: perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 2006;66:9339-44.
48. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25:3818-22.
49. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea: a paradigm shift. Cancer Res. 2006;66:1883-90 [discussion 95-6].
50. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology. 2004;39:1477-87.
51. Thorgeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology. 2006;43:2-8.
52. Villanueva A, Newell P, Chiang D, Friedman S, Llovet JM. Genes and signaling pathways involved in the pathogenesis of HCC. Semin Liver Dis. 2007;27:55-76.